Kyverna Therapeutics (KYTX) Debt Ratio (2025 - 2026)

Kyverna Therapeutics' (KYTX) quarterly Debt Ratio came in at 0.1 in Q1 2026, up 14.64% on a QoQ basis from 0.08 in Q4 2025.

Kyverna Therapeutics (KYTX) Debt Ratio (2025 - 2026) Analysis & Trends

Kyverna Therapeutics (KYTX) has 2 years of Debt Ratio data on file, last reported at 0.1 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.1 (changed N/A YoY) and the FY2025 annual result came in at 0.08, changed N/A from the prior year.
Debt Ratio rose to 0.1 in Q1 2026, from 0.08 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.1 in Q1 2026 to a low of 0.08 in Q4 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Kyverna Therapeutics	505.26 Mn	505.26 Mn	-	0.11

Historic Data

Download Data

Date	Value
Jun 30, 2026	0.11
Mar 31, 2026	0.10
Dec 31, 2025	0.08